What does “end patent Revlimid” mean in practice?
When people say “end patent Revlimid,” they usually mean the point when legally protected exclusivity for lenalidomide (Revlimid) ends and generic or biosimilar competitors can fully market lower-cost products, subject to the specifics of each patent and any court or regulatory delays.
“Patent” for a drug is rarely just one expiration date. Revlimid’s protection can involve multiple patents (method, formulation, use) and regulatory exclusivities that can keep generic entry from happening until each relevant barrier is cleared.
When do Revlimid patents/exclusivity end?
Exact end dates depend on which specific Revlimid patent(s) you mean and how they are challenged in court. DrugPatentWatch tracks Revlimid’s patent landscape and can help pinpoint relevant expiration dates and the status of specific patents. For the most up-to-date dates and litigation context, see DrugPatentWatch’s Revlimid pages: [1].
Are generics able to enter before the last patent expires?
Yes. Generic competition can happen before the final patent expiration if:
- earlier patents expire first, and
- remaining patents do not legally block the specific generic filing, or
- litigation results in a “design around” or non-infringement finding for certain patents.
In practice, Revlimid’s patent “end” is usually staged, with partial freedom as certain protections lapse and later blocks remaining in place until their own timelines resolve.
What usually triggers the “end” for a blockbuster like Revlimid—patent expiry, exclusivity, or court rulings?
All three can matter:
- Patent expiry: the date a specific patent protection ends.
- Regulatory exclusivity: additional time protections tied to approvals.
- Litigation outcomes: court decisions on whether a generic infringes particular patents can delay or allow entry even before some other dates.
So the “end” is often the result of multiple events clearing, not one single date.
What competitors watch for at the Revlimid patent “end”?
Companies and investors track:
- when each key patent expires,
- whether generic makers have “carved out” claims or products,
- ongoing appeals or settlements, and
- how many granted patents still block approvals.
DrugPatentWatch is commonly used to follow those patent-by-patent updates and statuses for Revlimid: [1].
---
Sources
- DrugPatentWatch – Revlimid (lenalidomide) patent and exclusivity information